Overview

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Status:
Not yet recruiting

Trial end date:
2026-01-16

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

Ipilimumab